Published in Gynecol Oncol on January 19, 2006
Treatment options in recurrent cervical cancer (Review). Oncol Lett (2010) 0.92
Total pelvic exenteration for gynecologic malignancies. Int J Surg Oncol (2012) 0.89
Modified vertical rectus abdominis myocutaneous flap vaginal reconstruction: an analysis of surgical outcomes. Gynecol Oncol (2011) 0.86
Pelvic exenteration for advanced and recurrent malignancy. World J Surg (2010) 0.86
Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol (2014) 0.85
Morbidity and outcome of pelvic exenteration in locally advanced pelvic malignancies. Indian J Surg Oncol (2012) 0.81
Postoperative outcomes after continent versus incontinent urinary diversion at the time of pelvic exenteration for gynecologic malignancies. Gynecol Oncol (2013) 0.81
Surgical results of pelvic exenteration in the treatment of gynecologic cancer. World J Surg Oncol (2014) 0.79
Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea. J Gynecol Oncol (2012) 0.79
Extended abdominoperineal resection in women: the Barbadian experience. Int Semin Surg Oncol (2007) 0.78
Role of MR Imaging and FDG PET/CT in Selection and Follow-up of Patients Treated with Pelvic Exenteration for Gynecologic Malignancies. Radiographics (2015) 0.78
The effect of body mass index on surgical outcomes and survival following pelvic exenteration. Gynecol Oncol (2012) 0.75
Salvage Surgery for Cervical Cancer Recurrences. Indian J Surg Oncol (2015) 0.75
Vulva reconstruction after pelvic exenteration, using a unique combination of two flaps. BMJ Case Rep (2011) 0.75
Permanent interstitial re-irradiation with Au-198 seeds in patients with post-radiation locally recurrent uterine carcinoma. J Radiat Res (2012) 0.75
Anterior pelvic exenteration for exstrophic bladder adenocarcinoma: Case report and review. Int J Surg Case Rep (2016) 0.75
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol (2013) 5.40
Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol (2006) 3.53
Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol (2008) 3.20
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis (2013) 3.06
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin (2007) 2.81
Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. Am J Obstet Gynecol (2007) 2.22
A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev (2008) 2.01
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. J Low Genit Tract Dis (2015) 1.73
Outcomes after an excisional procedure for cervical intraepithelial neoplasia in HIV-infected women. Gynecol Oncol (2010) 1.64
Human papillomavirus and cervical cancer. Lancet (2013) 1.48
Does the number of nodes removed impact survival in vulvar cancer patients with node-negative disease? Gynecol Oncol (2010) 1.47
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis (2010) 1.37
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol (2015) 1.30
Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol (2009) 1.21
Overcoming the barriers to HPV vaccination in high-risk populations in the US. Gynecol Oncol (2010) 1.19
In vivo light scattering measurements for detection of precancerous conditions of the cervix. Gynecol Oncol (2007) 1.18
Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). Gynecol Oncol (2007) 1.16
Therapy of human papillomavirus-related disease. Vaccine (2012) 1.11
Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res (2010) 1.03
Association of bactericidal activity of genital tract secretions with Escherichia coli colonization in pregnancy. Am J Obstet Gynecol (2012) 0.98
Evaluation of 3 approaches for assessing adherence to vaginal gel application in clinical trials. Sex Transm Dis (2013) 0.98
In vivo light scattering for the detection of cancerous and precancerous lesions of the cervix. Appl Opt (2009) 0.96
Extended-field radiotherapy and high-dose-rate brachytherapy in carcinoma of the uterine cervix: clinical experience with and without concomitant chemotherapy. Cancer (2003) 0.95
Obesity and age at diagnosis of endometrial cancer. Obstet Gynecol (2014) 0.95
Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer. Gynecol Oncol (2009) 0.95
Survival for stage IB cervical cancer with positive lymph node involvement: a comparison of completed vs. abandoned radical hysterectomy. Gynecol Oncol (2008) 0.95
Definitive radiation therapy for endometrial cancer in medically inoperable elderly patients. Brachytherapy (2010) 0.93
Co-expression of GPR30 and ERbeta and their association with disease progression in uterine carcinosarcoma. Am J Obstet Gynecol (2010) 0.93
Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol Oncol (2007) 0.93
Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications. Gynecol Oncol (2009) 0.92
Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine. Hum Vaccin (2010) 0.92
Genital tract HIV RNA levels and their associations with human papillomavirus infection and risk of cervical precancer. J Acquir Immune Defic Syndr (2014) 0.91
Detection of cervical intraepithelial neoplasias and cancers in cervical tissue by in vivo light scattering. J Low Genit Tract Dis (2009) 0.90
High-dose-rate Rotte "Y" applicator brachytherapy for definitive treatment of medically inoperable endometrial cancer: 10-year results. Int J Radiat Oncol Biol Phys (2008) 0.90
Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6. Cancer Biol Ther (2010) 0.90
High-dose rate brachytherapy (HDRB) for primary or recurrent cancer in the vagina. Radiat Oncol (2008) 0.89
Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas. Int J Gynecol Pathol (2002) 0.88
Cervical intraepithelial neoplasia is associated with genital tract mucosal inflammation. Sex Transm Dis (2012) 0.88
USA endometrial cancer projections to 2030: should we be concerned? Future Oncol (2014) 0.87
Dual-console robotic surgery compared to laparoscopic surgery with respect to surgical outcomes in a gynecologic oncology fellowship program. Gynecol Oncol (2012) 0.87
Association Between Statin Use and Endometrial Cancer Survival. Obstet Gynecol (2015) 0.87
Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive. PLoS One (2012) 0.87
Persistent low levels of human chorionic gonadotropin: A premalignant gestational trophoblastic disease. Am J Obstet Gynecol (2003) 0.86
Arteriovenous malformations of the uterus: long-term follow-up. Gynecol Obstet Invest (2008) 0.86
Surgery versus radiation therapy for stage IB2 cervical carcinoma: a population-based analysis. Int J Gynecol Cancer (2012) 0.86
Survival and toxicity differences between 5-day and weekly cisplatin in patients with locally advanced cervical cancer. Cancer (2007) 0.86
Vaccine strategies for human papillomavirus-associated cancers. Curr Opin Oncol (2005) 0.85
Performance of implementing guideline-driven cervical cancer screening measures in an inner-city hospital system. J Low Genit Tract Dis (2011) 0.85
Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study. Gynecol Oncol (2009) 0.85
Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. Gynecol Oncol (2004) 0.84
A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecol Oncol (2009) 0.84
What is the role of HPV typing in the United States now and in the next five years in a vaccinated population? Gynecol Oncol (2010) 0.84
Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecol Oncol (2005) 0.84
Preoperative intensity-modulated radiotherapy and chemotherapy for locally advanced vulvar carcinoma. Gynecol Oncol (2008) 0.84
High prevalence of high grade anal intraepithelial neoplasia in HIV-infected women screened for anal cancer. J Acquir Immune Defic Syndr (2012) 0.83
How does public policy impact cervical screening and vaccination strategies? Gynecol Oncol (2010) 0.83
Three-dimensional image-based high-dose-rate interstitial brachytherapy for vaginal cancer. Brachytherapy (2011) 0.83
Use of the dye stain assay and ultraviolet light test for assessing vaginal insertion of placebo-filled applicators before and after sex. Sex Transm Dis (2013) 0.83
Heavy cervical cancer burden in elderly women: how can we improve the situation? Acta Cytol (2012) 0.82
Decentralizing Maternity Services to Increase Skilled Attendance at Birth and Antenatal Care Utilization in Rural Rwanda: A Prospective Cohort Study. Matern Child Health J (2015) 0.82
A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer. Am J Clin Oncol (2010) 0.82
Human papillomavirus testing for triage of women with low-grade squamous intraepithelial lesions. Int J Cancer (2012) 0.82
Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. Gynecol Oncol (2006) 0.82
Two fractions of high-dose-rate brachytherapy in the management of cervix cancer: clinical experience with and without chemotherapy. Int J Radiat Oncol Biol Phys (2002) 0.82
Mucinous tumors of the ovary: diagnostic challenges at frozen section and clinical implications. Gynecol Oncol (2011) 0.81
High-dose-rate interstitial computed tomography-based brachytherapy for the treatment of cervical cancer: early results. Brachytherapy (2012) 0.81
Risk factors for poor prognosis in microinvasive adenocarcinoma of the uterine cervix (IA1 and IA2): a pooled analysis. Gynecol Oncol (2010) 0.81
Risk factors for persistent cervical intraepithelial neoplasia grades 1 and 2: managed by watchful waiting. J Low Genit Tract Dis (2011) 0.81
Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women. AIDS (2013) 0.81
Preoperative intensity modulated radiation therapy and chemotherapy for locally advanced vulvar carcinoma: analysis of pattern of relapse. Int J Radiat Oncol Biol Phys (2012) 0.80
Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report. Int J Gynecol Cancer (2011) 0.80
Histopathologic differences account for racial disparity in uterine cancer survival. Gynecol Oncol (2012) 0.80
Complete metabolic response after definitive radiation therapy for cervical cancer: patterns and factors predicting for recurrence. Gynecol Oncol (2012) 0.79
The risk of subsequent malignancies in women with uterine papillary serous or clear cell endometrial cancers. Int J Gynecol Cancer (2013) 0.79
Intraperitoneal catheter leads to prolongation of the time to normalization of serum CA125 levels. Int J Gynecol Cancer (2010) 0.79
Cervical neoplasia complicating pregnancy. Obstet Gynecol Clin North Am (2005) 0.79
Uterine artery embolization in the management of vaginal bleeding from cervical pregnancy: a case series. J Reprod Med (2005) 0.79
Primary plasmacytoma arising in an endocervical polyp with detection of neoplastic cells on papanicolaou test. A case report and review of the literature. Arch Pathol Lab Med (2003) 0.79
High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine. HIV Clin Trials (2013) 0.78
ASCCP Colposcopy Standards: Risk-Based Colposcopy Practice. J Low Genit Tract Dis (2017) 0.78
Alpha-tocopherol and alpha-tocopheryl quinone levels in cervical intraepithelial neoplasia and cervical cancer. Am J Obstet Gynecol (2004) 0.77
Efficacy and toxicity of concomitant cisplatin with external beam pelvic radiotherapy and two high-dose-rate brachytherapy insertions for the treatment of locally advanced cervical cancer. Gynecol Oncol (2007) 0.77
Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia. Gynecol Oncol (2009) 0.77
Gestation trophoblastic diseases: management of cases with persistent low human chorionic gonadotropin results. Obstet Gynecol Clin North Am (2005) 0.75
Topical hexaminolevulinate photodynamic therapy for the treatment of persistent human papilloma virus infections and cervical intraepithelial neoplasia. Expert Opin Investig Drugs (2014) 0.75
Screening for Anal Cancer in Women. J Low Genit Tract Dis (2015) 0.75
Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium. Gynecol Oncol (2005) 0.75
Comparison of Locoregional Recurrence with Mastectomy vs. Breast Conserving Surgery in Pregnancy Associated Breast Cancer (PABC). Cancers (Basel) (2009) 0.75
Systematic Review of International Colposcopy Quality Improvement Guidelines. J Low Genit Tract Dis (2017) 0.75
Evaluation of low-dose intraperitoneal interferon-alpha for palliation of ascites in patients with non-ovarian gynecologic malignancies. Gynecol Oncol (2003) 0.75